Intervention Protocol

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

  1. Maria José Martinez-Zapata1,*,
  2. Arturo J Martí-Carvajal2,
  3. Ivan Solà3,
  4. José I Pijoán4,
  5. José A Buil-Calvo5

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 8 SEP 2010

DOI: 10.1002/14651858.CD008721

How to Cite

Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Pijoán JI, Buil-Calvo JA. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008721. DOI: 10.1002/14651858.CD008721.

Author Information

  1. 1

    Universitat Autònoma de Barcelona, Iberoamerican Cochrane Centre. CIBER Epidemiología y Salud Pública (CIBERESP), Spain. IIB Sant Pau, Barcelona, Catalonia, Spain

  2. 2

    Iberoamerican Cochrane Network, Valencia, Edo. Carabobo, Venezuela

  3. 3

    IIB Sant Pau, Iberoamerican Cochrane Centre, Barcelona, Catalunya, Spain

  4. 4

    Hospital de Cruces, Barakaldo, Pais Vasco, Spain

  5. 5

    Hospital de la Santa Creu i Sant Pau, Oftalmology, Barcelona, Catalonian, Spain

*Maria José Martinez-Zapata, Iberoamerican Cochrane Centre. CIBER Epidemiología y Salud Pública (CIBERESP), Spain. IIB Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M. Claret 171, Casa de Convalescència, Barcelona, Catalonia, 08041, Spain. mmartinezz@santpau.es.

Publication History

  1. Publication Status: New
  2. Published Online: 8 SEP 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective is to determine the efficacy of selective vascular endothelial growth factor inhibitors (anti-VEGFs) for treating patients with proliferative diabetic retinopathy (DR).
The secondary objective is to assess the safety of selective anti-VEGFs for treating patients with proliferative DR.